Refractory Neovascular Age-related Macular Degeneration Secondary to Polypoidal Choroidal Vasculopathy

purpose : To describe a neovascular pattern associated with treatment-refractory neovascular age-related macular degeneration (AMD). Design A retrospective observational case series. Methods setting: Clinical practice. patient population: Twelve eyes of 12 patients with neovascular AMD in which a poor anatomic response to anti–vascular endothelial growth factor (VEGF) therapy was related to polypoidal choroidal vasculopathy (PCV). observation procedure: Slit-lamp biomicroscopy, optical coherence tomography, fluorescein and indocyanine green angiography. main outcome measures: Snellen visual acuity (VA), anatomic response to therapy including presence or absence of retinal edema, hemorrhage, and lipid exudates. Results New or persistent PCV was identified in a cohort of patients demonstrating increasing macular exudation despite regular intravitreal ranibizumab (Lucentis; Genentech Inc, South San Francisco, California, USA) or bevacizumab (Avastin; Genentech Inc) injections for a minimum of 6 months. Treatment with verteporfin photodynamic therapy (PDT), PDT/anti-VEGF combination therapy, or continued anti-VEGF monotherapy resulted in complete resolution of exudation in 9 of 12 patients and partial resolution of exudation in the remaining 3 patients. Conclusion Treatment-refractory neovascular AMD may harbor vascular abnormalities such as PCV. Modifications in therapeutic protocols may be indicated in order to improve visual and anatomic outcomes in this population.